https://www.forbes.com/companies/epizyme/

I find it interesting that here we have a company formed in 2012 doing clinical trals using a epigenetics platform with quite a large market cap (750 mil usd )listed on Nasdaq and Zenith can't even put out one NR on a year long trial with some of the most highly regarded clinicians in their respected fields ,  Why so silent, if the trial are going so spectacular why not release some preliminary results, Unless they are in deep negotiations with BP, This makes absoulte no sense why they are so quiet..  I realize that being a private firm has its perks to information flow but this is ridiculous.....

Maybe Zenith management can learn something from Epizyme on  how to create an effective publicly traded market cap  in hugely growing epigenetics field....